Santarus Inc., of San Diego, and Pharming Group NV, of Leiden, the Netherlands, announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb study evaluating the investigational drug Rhucin (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedema in patients with hereditary angioedema.